Aerovate Therapeutics Aktie
WKN DE: A3CTMQ / ISIN: US0080641071
08.07.2024 14:58:01
|
Aerovate To Begin Review Of Strategic Alternatives
(RTTNews) - Aerovate Therapeutics, Inc. (AVTE) announced on Monday that it will conduct a comprehensive review of strategic alternatives with a focus to maximize shareholder value.
The company has engaged Wedbush PacGrow as the company's exclusive strategic financial advisor to assist in the process, which may include but are not limited to, an acquisition, merger, reverse merger, business combination, and others.
Earlier, the drug maker had announced its decision to halt enrollment and shutdown of the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial as well as the long-term extension study.
AVTE was trading up by 3.11 percent at $1.660 in the pre-market trade on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Aerovate Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Aerovate Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Aerovate Therapeutics Inc Registered Shs | 2,47 | -1,59% |
|